EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Blinatumomab exposure prior to allogeneic stem cell transplantation is associated with increased Epstein-Barr virus reactivation

Hai-Lu Sun, Zhi-Fan Zhao, Xian-Ying Yin, Meng Lv, Ling Ma, Fang-Fang Wei, Xiao-Su Zhao, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang, Xu-Ying Pei

Annals of Hematology · 2026

DOI: 10.1007/s00277-026-06738-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2026. Verfasst von Hai-Lu Sun und 11 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking Uni…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Virus Activation, Herpesvirus 4, Human, Epstein-Barr Virus Infections. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, Major Program of the National Natural Science Foundation of China, Being Nova Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blinatumomab, a CD19/CD3 bispecific T-cell engager, is frequently used for B-cell acute lymphoblastic leukemia (B-ALL) prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although its efficacy in achieving measurable residual disease negativity is well established, its profound B-cell depletion and potential immunomodulatory effects may exacerbate post-transplant viral reactivation risks, particularly in the context of the inherent immunosuppression associated with allo-HSCT. In this matched retrospective cohort study, we identified 97 consecutive B-ALL patients who received blinatumomab prior to allo-HSCT between January 2021 and December 2024. Using 1:2 propensity score matching based on gender, age, and pre-transplant chemotherapy regimen, we selected 194 control patients from the same period who underwent allo-HSCT without prior blinatumomab exposure. Clinical outcomes were compared between the two cohorts. By day 100, EBV viremia incidence was significantly higher in the blinatumomab group (41.5% vs. 26.4%, p = 0.009), with blinatumomab identified as an independent risk factor (HR = 1.792, 95% CI 1.206–2.661, p = 0.004). Notably, immunoglobulin analysis revealed markedly lower IgA levels in the blinatumomab group (0.298 vs. 0.544 g/L, p < 0.001), while T-cell (CD3+/CD4+/CD8+) and B-cell (CD19+) reconstitution did not differ. One-year overall survival (OS) and non-relapse mortality (NRM) were also comparable. Blinatumomab exposure is associated with increased EBV reactivation post-allo-HSCT, likely linked to humoral immunity impairment. These findings underscore the need for enhanced EBV monitoring in this population after allo-HSCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationVirus ActivationHerpesvirus 4, HumanEpstein-Barr Virus InfectionsAntibodies, BispecificHumansFemaleMaleRetrospective StudiesTransplantation, HomologousAdultAdolescentMiddle AgedYoung AdultPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Stichwörter der Autor:innen

Acute lymphoblastic leukemiaAllogeneic stem cell transplantationBlinatumomabEBV viremia

Substanzen

blinatumomabAntibodies, Bispecific

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, Beijing Key Laboratory of Cell and Gene Therapy for Hematolog…
  • Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
  • Collaborative Innovation Center of Hematology, Beijing University, Beijing, China.
  • Collaborative Innovation Center of Hematology, Beijing University, Beijing, China. peixuying@pku.edu.cn.

Förderung

  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • Major Program of the National Natural Science Foundation of China
  • Being Nova Program
  • Beijing Municipal Science & Technology Commission
  • Peking University Medicine Fund for world's leading discipline or discipline cluster development

Zitieren

APA

Sun, H. L., Zhao, Z. F., Yin, X. Y., Lv, M., Ma, L., Wei, F. F., Zhao, X. S., Wang, Y., Xu, L. P., Zhang, X. H., Huang, X. J., & Pei, X. Y. (2026). Blinatumomab exposure prior to allogeneic stem cell transplantation is associated with increased Epstein-Barr virus reactivation. Annals of Hematology. https://doi.org/10.1007/s00277-026-06738-2

Vancouver

Sun HL, Zhao ZF, Yin XY, Lv M, Ma L, Wei FF, et al. Blinatumomab exposure prior to allogeneic stem cell transplantation is associated with increased Epstein-Barr virus reactivation. Annals of Hematology. 2026. doi:10.1007/s00277-026-06738-2

BibTeX
@article{Sun2026,
  author = {Sun, Hai-Lu and Zhao, Zhi-Fan and Yin, Xian-Ying and Lv, Meng and Ma, Ling and Wei, Fang-Fang and Zhao, Xiao-Su and Wang, Yu and Xu, Lan-Ping and Zhang, Xiao-Hui and Huang, Xiao-Jun and Pei, Xu-Ying},
  title = {Blinatumomab exposure prior to allogeneic stem cell transplantation is associated with increased Epstein-Barr virus reactivation},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-06738-2}
}
Kostenlos starten →